SEC Form 4 · accession 0000899866-17-000149
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Clancy
Officer — EVP, Chief Financial Officer
Period of report
Jul 10, 2017
Accepted (ET)
Jul 12, 2017 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Jul 10, 2017 | A | 46,865 | $0.00 | A | 46,865 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $123.76 | Jul 10, 2017 | A | 29,089 | A | Jul 10, 2018 | Jul 10, 2027 | Common Stock, par value $.0001 per share | 29,089 | 29,089 | D |
Explanation of responses
- F1Award of Restricted Stock Units under 2017 Incentive Plan. 25% vest on each anniversary of the grant date.
- F2Award of Stock Options under 2017 Incentive Plan. 25% vest on the one year anniversary of the grant date and 1/16th every 90 days thereafter.